These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 37657693)

  • 1. Engineered peptide-drug conjugate provides sustained protection of retinal ganglion cells with topical administration in rats.
    Hsueh HT; Chou RT; Rai U; Kolodziejski P; Liyanage W; Pejavar J; Mozzer A; Davison C; Appell MB; Kim YC; Leo KT; Kwon H; Sista M; Anders NM; Hemingway A; Rompicharla SVK; Pitha I; Zack DJ; Hanes J; Cummings MP; Ensign LM
    J Control Release; 2023 Oct; 362():371-380. PubMed ID: 37657693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A hypotonic gel-forming eye drop provides enhanced intraocular delivery of a kinase inhibitor with melanin-binding properties for sustained protection of retinal ganglion cells.
    Kim YC; Hsueh HT; Shin MD; Berlinicke CA; Han H; Anders NM; Hemingway A; Leo KT; Chou RT; Kwon H; Appell MB; Rai U; Kolodziejski P; Eberhart C; Pitha I; Zack DJ; Hanes J; Ensign LM
    Drug Deliv Transl Res; 2022 Apr; 12(4):826-837. PubMed ID: 33900546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eye drop delivery of pigment epithelium-derived factor-34 promotes retinal ganglion cell neuroprotection and axon regeneration.
    Vigneswara V; Esmaeili M; Deer L; Berry M; Logan A; Ahmed Z
    Mol Cell Neurosci; 2015 Sep; 68():212-21. PubMed ID: 26260110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topical Delivery of Anti-VEGF Drugs to the Ocular Posterior Segment Using Cell-Penetrating Peptides.
    de Cogan F; Hill LJ; Lynch A; Morgan-Warren PJ; Lechner J; Berwick MR; Peacock AFA; Chen M; Scott RAH; Xu H; Logan A
    Invest Ophthalmol Vis Sci; 2017 May; 58(5):2578-2590. PubMed ID: 28494491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo effects of single or combined topical neuroprotective and regenerative agents on degeneration of retinal ganglion cells in rat optic nerve crush model.
    Kitamura Y; Bikbova G; Baba T; Yamamoto S; Oshitari T
    Sci Rep; 2019 Jan; 9(1):101. PubMed ID: 30643179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroprotective effects of topical coenzyme Q10 + vitamin E in mechanic optic nerve injury model.
    Ekicier Acar S; Sarıcaoğlu MS; Çolak A; Aktaş Z; Sepici Dinçel A
    Eur J Ophthalmol; 2020 Jul; 30(4):714-722. PubMed ID: 30852912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Sustained Release of Tafluprost with a Drug Delivery System Prevents the Axonal Injury-induced Loss of Retinal Ganglion Cells in Rats.
    Sato K; Nakagawa Y; Omodaka K; Asada H; Fujii S; Masaki K; Nakazawa T
    Curr Eye Res; 2020 Sep; 45(9):1114-1123. PubMed ID: 31994948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Y-P30 confers neuroprotection after optic nerve crush in adult rats.
    Macharadze T; Landgraf P; Pape HC; Wahle P; Kreutz MR
    Neuroreport; 2011 Aug; 22(11):544-7. PubMed ID: 21666514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topical administration of a Rock/Net inhibitor promotes retinal ganglion cell survival and axon regeneration after optic nerve injury.
    Shaw PX; Sang A; Wang Y; Ho D; Douglas C; Dia L; Goldberg JL
    Exp Eye Res; 2017 May; 158():33-42. PubMed ID: 27443501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving corneal permeability of dexamethasone using penetration enhancing agents: First step towards achieving topical drug delivery to the retina.
    Thareja A; Leigh T; Hakkarainen JJ; Hughes H; Alvarez-Lorenzo C; Fernandez-Trillo F; Blanch RJ; Ahmed Z
    Int J Pharm; 2024 Jul; 660():124305. PubMed ID: 38852749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroprotective effect of nipradilol [3,4-dihydro-8-(2-hydroxy-3-isopropylamino)-propoxy-3-nitroxy-2H-1-benzopyran] in a rat model of optic nerve degeneration.
    Karim MZ; Sawada A; Mizuno K; Kawakami H; Ishida K; Yamamoto T
    J Glaucoma; 2009 Jan; 18(1):26-31. PubMed ID: 19142131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A combination of topical and systemic administration of brimonidine is neuroprotective in the murine optic nerve crush model.
    Maciulaitiene R; Kalesnykas G; Pauza DH; Januleviciene I
    PLoS One; 2024; 19(8):e0308671. PubMed ID: 39116180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ocular hypotensive effects of topically administered agmatine in a chronic ocular hypertensive rat model.
    Hong S; Kim CY; Lee WS; Shim J; Yeom HY; Seong GJ
    Exp Eye Res; 2010 Jan; 90(1):97-103. PubMed ID: 19782071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Machine learning-driven multifunctional peptide engineering for sustained ocular drug delivery.
    Hsueh HT; Chou RT; Rai U; Liyanage W; Kim YC; Appell MB; Pejavar J; Leo KT; Davison C; Kolodziejski P; Mozzer A; Kwon H; Sista M; Anders NM; Hemingway A; Rompicharla SVK; Edwards M; Pitha I; Hanes J; Cummings MP; Ensign LM
    Nat Commun; 2023 May; 14(1):2509. PubMed ID: 37130851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topical bromfenac transiently delays axotomy-induced retinal ganglion cell loss.
    Rovere G; Nadal-Nicolás FM; Sobrado-Calvo P; Villegas-Pérez MP; Vidal-Sanz M; Agudo-Barriuso M
    Exp Eye Res; 2019 May; 182():156-159. PubMed ID: 30940447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced neuroprotective activity of ophthalmic delivered nerve growth factor conjugated with cell penetrating peptide against optic nerve injury.
    Zhu D; Li Y; Zhang J; Chen Y; Song X; Chen W; Wu S; Hou L
    J Drug Target; 2024 Dec; 32(1):93-99. PubMed ID: 38105766
    [No Abstract]   [Full Text] [Related]  

  • 17. Delivery of Topically Applied Calpain Inhibitory Peptide to the Posterior Segment of the Rat Eye.
    Ozaki T; Nakazawa M; Yamashita T; Ishiguro S
    PLoS One; 2015; 10(6):e0130986. PubMed ID: 26107400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experimental and clinical evidence of neuroprotection by nerve growth factor eye drops: Implications for glaucoma.
    Lambiase A; Aloe L; Centofanti M; Parisi V; Báo SN; Mantelli F; Colafrancesco V; Manni GL; Bucci MG; Bonini S; Levi-Montalcini R
    Proc Natl Acad Sci U S A; 2009 Aug; 106(32):13469-74. PubMed ID: 19805021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topical administration of rapamycin promotes retinal ganglion cell survival and reduces intraocular pressure in a rat glaucoma model.
    Wang F; Ma F; Song Y; Li N; Li X; Pang Y; Hu P; Shao A; Deng C; Zhang X
    Eur J Pharmacol; 2020 Oct; 884():173369. PubMed ID: 32712092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Kallikrein-binding protein promotes axonal regeneration and protect rat retinal ganglion cells following optic nerve injury].
    Jin SX; Zeng Y; Wan J; Wan K; Li YY; Li LY; Wang TH; Feng ZT; Li Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Apr; 30(4):738-41. PubMed ID: 20423839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.